Human immunodeficiency virus (HIV) is a chronic disease associated with dyslipidemia and
insulin resistance. In addition, the administration of combination antiretroviral therapy is …

Dyslipidemia and lipid management in HIV-infected patients : Current Opinion in Endocrinology,
Diabetes and Obesity Dyslipidemia and lipid management in HIV-infected patients : Current …

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. Asthis
population lives longer, coronary heart disease has become an important comorbid …

Since the discovery and development of antiretroviral therapy (ART), HIV has become a
chronic disease with patients living longer lives and to ages where co‐morbidities, such as …

Patients infected with HIV have a high risk of developing dyslipidemia. Effective therapeutic
strategies can be challenging due to an increase risk of drug interactions and other …

HIV-infected patients have metabolic abnormalities that put them at increased risk of
cardiovascular disease (CVD), including abnormalities associated with HIV infection itself …

Introduction: Statin therapy is widely used across the globe for the treatment and prevention
of cardiovascular disease (CVD). It is well established that statin therapy is associated with …

Dyslipidemia now is recognized as a significant potential adverse event in HIV-infected
patients who are receiving antiretroviral therapy. HIV-infected persons who have …

Effectiveness of lipid-lowering therapy in HIV patients : Current Opinion in HIV and AIDS
Effectiveness of lipid-lowering therapy in HIV patients : Current Opinion in HIV and AIDS Log in …

Since the introduction of HAART, there was a remarkably change in the natural history of
HIV disease, leading to a notable extension of life expectancy, although prolonged …